Overview

A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM

Status:
Completed
Trial end date:
2021-06-03
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy and safety of DBPR108 tablets in combination with metformin hydrochloride in the treatment of type 2 diabetes mellitus. A total of 210 subjects will be randomly assigned in a ratio of 2:1 to receive metformin hydrochloride plus DBPR108 or metformin hydrochloride plus placebo.
Phase:
Phase 3
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Treatments:
Metformin